[go: up one dir, main page]

BRPI0816553A2 - "composto, composição farmcêutica, uso de uma composição, uso de um composto, e, processo para a preparação de um composto" - Google Patents

"composto, composição farmcêutica, uso de uma composição, uso de um composto, e, processo para a preparação de um composto"

Info

Publication number
BRPI0816553A2
BRPI0816553A2 BRPI0816553A BRPI0816553A BRPI0816553A2 BR PI0816553 A2 BRPI0816553 A2 BR PI0816553A2 BR PI0816553 A BRPI0816553 A BR PI0816553A BR PI0816553 A BRPI0816553 A BR PI0816553A BR PI0816553 A2 BRPI0816553 A2 BR PI0816553A2
Authority
BR
Brazil
Prior art keywords
compound
composition
preparation
pharmaceutical composition
pharmaceutical
Prior art date
Application number
BRPI0816553A
Other languages
English (en)
Inventor
Johnson Francis
S Kovach John
Original Assignee
Lixte Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lixte Biotechnology Inc filed Critical Lixte Biotechnology Inc
Publication of BRPI0816553A2 publication Critical patent/BRPI0816553A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
BRPI0816553A 2007-10-01 2008-10-01 "composto, composição farmcêutica, uso de uma composição, uso de um composto, e, processo para a preparação de um composto" BRPI0816553A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US99733807P 2007-10-01 2007-10-01
US867307P 2007-12-21 2007-12-21
US6396508P 2008-02-06 2008-02-06
PCT/US2008/011367 WO2009045440A1 (en) 2007-10-01 2008-10-01 Hdac inhibitors

Publications (1)

Publication Number Publication Date
BRPI0816553A2 true BRPI0816553A2 (pt) 2017-07-18

Family

ID=40526543

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0816553A BRPI0816553A2 (pt) 2007-10-01 2008-10-01 "composto, composição farmcêutica, uso de uma composição, uso de um composto, e, processo para a preparação de um composto"

Country Status (11)

Country Link
US (2) US8143445B2 (pt)
EP (1) EP2200439B1 (pt)
JP (1) JP5730575B2 (pt)
CN (1) CN101854804B (pt)
AU (1) AU2008307541B2 (pt)
BR (1) BRPI0816553A2 (pt)
CA (1) CA2700857C (pt)
EA (1) EA018618B1 (pt)
ES (1) ES2628748T3 (pt)
MX (1) MX2010003417A (pt)
WO (1) WO2009045440A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090018142A9 (en) * 2006-05-02 2009-01-15 Zhengping Zhuang Use of phosphatases to treat tumors overexpressing N-CoR
CN103788108B (zh) 2007-02-06 2017-04-12 利克斯特生物技术公司 氧杂双环庚烷和氧杂双环庚烯，它们的制备及用途
WO2009020565A1 (en) * 2007-08-03 2009-02-12 Lixte Biotechnology, Inc. Use of phosphates to treat neuroblastomas and medullogastomas
CN101854804B (zh) 2007-10-01 2014-07-23 利克斯特生物技术公司 Hdac抑制剂
US8738025B2 (en) 2008-05-30 2014-05-27 Alcatel Lucent Mobile-server protocol for location-based services
WO2010014141A1 (en) * 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
AU2009277086B2 (en) 2008-08-01 2015-12-10 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
ES2620027T3 (es) * 2008-09-03 2017-06-27 Biomarin Pharmaceutical Inc. Composiciones que incluyen derivados del ácido 6-aminohexanoico como inhibidores de HDAC
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
CA2828524C (en) 2011-02-28 2020-01-07 Repligen Corporation Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
WO2013154870A1 (en) 2012-04-10 2013-10-17 Annji Pharmaceutical Co., Ltd. Histone deacetylases (hdacs) inhibitors
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
CA2877167A1 (en) 2012-06-29 2014-01-03 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
DK2872631T3 (en) * 2012-07-13 2017-06-12 Turun Yliopisto COMBINATION THERAPY
US20160008336A1 (en) * 2013-03-05 2016-01-14 Lixte Biotechnology, Inc. Hdac inhibitors for the treatment of traumatic brain injury
BR112015023399A8 (pt) 2013-03-15 2019-12-03 Biomarin Pharm Inc inibidores de hdac, seu uso e composição farmacêutica
KR20160004299A (ko) 2013-04-09 2016-01-12 릭스트 바이오테크놀로지, 인코포레이티드 옥사바이시클로헵탄류 및 옥사바이시클로헵텐류의 제형
KR102408123B1 (ko) 2014-02-28 2022-06-10 고쿠리츠다이가쿠호진 도호쿠다이가쿠 아마이드 유도체
WO2016014783A1 (en) 2014-07-24 2016-01-28 H. Lee Moffitt Cancer Center And Research Institute, Inc. Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes
AU2016219853B2 (en) * 2015-02-19 2019-05-16 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders
HUE050177T2 (hu) 2015-05-15 2020-11-30 Lixte Biotechnology Inc Oxabicikloheptán elõvegyületek
WO2017044742A1 (en) * 2015-09-09 2017-03-16 The Regents Of The University Of California Novel cyp34a-specific inhibitors and methods of using same
CN116585480A (zh) 2016-12-08 2023-08-15 利克斯特生物技术公司 用于调节免疫应答的氧杂双环庚烷
RU2019136536A (ru) 2017-05-16 2021-06-16 Аннцзи Фармасьютикал Ко., Лтд. Ингибиторы гистондеацетилаз (hdac)
CN107954893A (zh) * 2017-11-28 2018-04-24 兰州纬寰生物科技有限公司 邻氨基苯甲酰胺衍生物及制备方法和用途
US20230212129A1 (en) 2020-06-08 2023-07-06 Annji Pharmaceutical Co., Ltd. Quinazoline derivatives useful as selective hdac6 inhibitors
CN113200885B (zh) * 2021-04-09 2023-01-06 南华大学 一种基于伏立诺他骨架的邻氨基苯甲酰胺类化合物及其制备与应用
US20250000847A1 (en) 2021-09-01 2025-01-02 Case Western Reserve University Treatment of neurodegenerative diseases with hdac inhibitors
WO2025079680A1 (ja) * 2023-10-13 2025-04-17 国立研究開発法人国立精神・神経医療研究センター 神経保護剤

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2957906A (en) * 1955-10-25 1960-10-25 Monsanto Chemicals Ketones
US3022268A (en) * 1958-07-17 1962-02-20 Du Pont Polyethylene composition
US4143054A (en) * 1977-11-04 1979-03-06 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane- and 7-oxabicycloheptene compounds
US4218478A (en) * 1979-01-05 1980-08-19 Ruiko Oiwa Trichostatin as an antiprotozoal agent
US4298752A (en) * 1980-09-19 1981-11-03 Regents Of The University Of California Cycloadduct precursors of cantharidin and method
US4410681A (en) * 1982-03-22 1983-10-18 The Dow Chemical Company Epoxy resins cured with salicyloyl hydrocarbylamines
US4614825A (en) * 1982-05-17 1986-09-30 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane and 7-oxabicycloheptene compounds
US4463015A (en) * 1982-08-18 1984-07-31 E. R. Squibb & Sons, Inc. Aryl substituted 7-oxabicycloheptane compounds, useful in inhibiting platelet aggregation
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
US4654355A (en) * 1985-08-01 1987-03-31 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane substituted amide-thioamide prostaglandin analogs
US4851553A (en) * 1986-06-04 1989-07-25 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane amido-carboxylic acids
US4816579A (en) * 1986-06-04 1989-03-28 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane amino-alcohol intermediates useful in making thromboxane A2 receptor antagonists
US4851423A (en) * 1986-12-10 1989-07-25 Schering Corporation Pharmaceutically active compounds
US5763647A (en) * 1990-03-30 1998-06-09 Shionogi & Co., Ltd. Preparation of optically active 1,4-bridged-cyclohexane carboxylic acid derivatives
US5266710A (en) * 1990-12-18 1993-11-30 Patel Ramesh N (Exo,exo)-7-oxabicyclo[2.2.1]heptane-2,3-dimethanol; monoacyl ester and diacyl ester
US5326898A (en) * 1992-02-11 1994-07-05 Allergan, Inc. Substituted phenylethenyl compounds having retinoid-like biological activity
US5770382A (en) * 1994-12-30 1998-06-23 Ligand Pharmaceuticals, Inc. Tricyclic retinoids, methods for their production and use
US6222055B1 (en) * 1995-07-06 2001-04-24 Fraunhofer-Gesellschaft Zur Foerderung Der Angwandten Forschung E.V. Hydrolyzable and polymerizable and/or polyadditive silanes
US5968965A (en) * 1996-01-30 1999-10-19 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6777217B1 (en) * 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US5925651A (en) * 1996-04-03 1999-07-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6387673B1 (en) * 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
ATE407683T1 (de) * 1997-10-15 2008-09-15 Polarx Biopharmaceuticals Inc Pharmazeutische zusammensetzungen enthaltend arsentrioxid zur behandlung von multiplen myelom
US6632823B1 (en) * 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
US20040110822A1 (en) * 1998-07-14 2004-06-10 The University Of Newcastle Research Associates Anhydride modified cantharidin analogues useful in the treatment of cancer
ES2261844T3 (es) * 1998-08-07 2006-11-16 Applied Research Systems Ars Holding N.V. Mimeticos de la fsh para el tratamiento de la infertilidad.
US20020151515A1 (en) * 1999-06-18 2002-10-17 Roberts Bruce L. Preparation and use of superior vaccines
US6949624B1 (en) * 1999-08-03 2005-09-27 The United States Of America As Represented By The Department Of Health And Human Services Cloning of the human nuclear receptor co-repressor gene
WO2001018171A2 (en) 1999-09-08 2001-03-15 Sloan-Kettering Institute For Cancer Research Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
US7605185B2 (en) * 1999-11-23 2009-10-20 Gerhart Graupner Treatment of arrhythmia by retinoids affecting signal transduction
EP1280764B1 (en) * 2000-03-24 2010-11-24 Methylgene, Inc. Inhibitors of histone deacetylase
US20090124690A1 (en) * 2000-04-03 2009-05-14 Alberte Randall S Generation of Combinatorial Synthetic Libraries and Screening for Novel Proadhesins and Nonadhesins
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
CN1471523A (zh) * 2000-09-21 2004-01-28 ʷ 咪唑类棉子糖激酶抑制剂
US6696483B2 (en) * 2000-10-03 2004-02-24 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
AU2001296661A1 (en) * 2000-10-06 2002-04-15 Michigan State University Divinyl ether synthase gene and protein, and uses thereof
CN1213050C (zh) * 2000-11-23 2005-08-03 拜尔公司 氧杂双环[2.2.1]庚烷衍生物，其制备方法和作为农药的用途
US20020177692A1 (en) * 2001-04-16 2002-11-28 Myriad Genetics, Incorporated BCL-XL-interacting protein and use thereof
AUPR392301A0 (en) * 2001-03-23 2001-04-26 University Of Newcastle Research Associates Limited, The Protein phosphatase inhibitors
US20040253637A1 (en) * 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US20050004839A1 (en) * 2001-05-04 2005-01-06 Anton Bakker Method and system for providing incentives based on a payment type
US20070015144A9 (en) * 2001-05-25 2007-01-18 Genset, S.A. Human cDNAs and proteins and uses thereof
WO2003014062A1 (en) * 2001-08-03 2003-02-20 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Acylthiols and component thiol compositions as anti-hiv and anti-retroviral agents
US7179450B2 (en) * 2001-09-20 2007-02-20 Medi-Physics, Inc. Methods for in vivo evaluation of pulmonary physiology and/or function using NMR signals of polarized Xe
WO2003032921A2 (en) * 2001-10-16 2003-04-24 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
CN100457183C (zh) 2001-11-06 2009-02-04 诺瓦提斯公司 环氧酶-2抑制剂/组蛋白脱乙酰酶抑制剂的组合
US7488712B2 (en) * 2002-02-20 2009-02-10 Kyushu Institute Of Technology Histone deacetylase inhibitors and methods for producing the same
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
EA011234B1 (ru) 2002-03-08 2009-02-27 Басф Акциенгезельшафт Фунгицидные смеси на базе протиоконазола с инсектицидом
US6809118B2 (en) * 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
NZ538686A (en) * 2002-09-23 2008-01-31 Schering Corp Novel imidazopyrazines as cyclin dependent kinase inhibitors
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1567860A4 (en) * 2002-11-05 2006-05-10 Univ California METHOD AND MATERIALS FOR THE INVESTIGATION OF PATHS ASSOCIATED WITH GLOBALBLASTOM PROGRESSION
GB0226855D0 (en) * 2002-11-18 2002-12-24 Queen Mary & Westfield College Histone deacetylase inhibitors
US20040197888A1 (en) * 2002-12-31 2004-10-07 Armour Christopher D. Alternatively spliced isoforms of histone deacetylase 3 (HDAC3)
WO2004064727A2 (en) * 2003-01-16 2004-08-05 Georgetown University Method of cancer treatment using hdac inhibitors
US7842835B2 (en) * 2003-07-07 2010-11-30 Georgetown University Histone deacetylase inhibitors and methods of use thereof
WO2005007151A1 (ja) * 2003-07-16 2005-01-27 Institute Of Medicinal Molecular Design. Inc. 皮膚色素沈着の治療剤
JP2007502287A (ja) * 2003-08-13 2007-02-08 アムジェン インコーポレイテッド メラニン凝集ホルモン受容体アンタゴニスト
WO2005025620A2 (en) * 2003-08-13 2005-03-24 Pharmacia Corporation Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents
US20070135365A1 (en) 2003-08-21 2007-06-14 Katsuyuki Tanizawa Pharmaceutical composition for preventing or remedying cardiac hypertrophy and cardiovascular disease caused thereby
US7378409B2 (en) * 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
US7094193B2 (en) * 2003-08-28 2006-08-22 Philip Morris Usa Inc. High speed laser perforation of cigarette tipping paper
EP1670466A4 (en) 2003-10-06 2007-04-25 Glaxo Group Ltd PREPARATION OF 1,6,7-TRISUBSTITUTED AZABENIC ZIMIDAZOLES AS KINASE-INHIBITORS
EP1678121A4 (en) * 2003-10-24 2007-07-25 Exelixis Inc MODULATORS OF TAO KINASES AND METHODS OF USE
EP1691891A2 (en) 2003-11-13 2006-08-23 The Board Of Regents, The University Of Texas System Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure
GB0328157D0 (en) 2003-12-04 2004-01-07 Imp College Innovations Ltd Compounds
WO2005058280A2 (en) 2003-12-12 2005-06-30 Myogen, Inc. Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
US8652502B2 (en) * 2003-12-19 2014-02-18 Cordis Corporation Local vascular delivery of trichostatin A alone or in combination with sirolimus to prevent restenosis following vascular injury
US20050283841A1 (en) 2004-02-02 2005-12-22 Mckinsey Timothy A Inhibition of protein kinase C-related kinase (PRK) as a treatment for cardiac hypertrophy and heart failure
US7253204B2 (en) * 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
US8299083B2 (en) 2004-08-17 2012-10-30 The Johns Hopkins University PDE5 inhibitor compositions and methods for treating cardiac indications
KR100677149B1 (ko) * 2004-11-12 2007-02-02 삼성전자주식회사 잉크 조성물
AU2006228957A1 (en) * 2005-04-01 2006-10-05 Methylgene Inc. Inhibitors of histone deacetylase
GB0511266D0 (en) 2005-06-02 2005-07-13 Trust Chemical compounds
EP1945242A2 (en) 2005-07-22 2008-07-23 The Regents of the University of Colorado, A Body Corporate Inhibition of extracellular signal-regulated kinase 1/2 as a treatment for cardiac hypertrophy and heart failure
AU2006280062A1 (en) * 2005-08-10 2007-02-22 Novartis Ag Method of use of deacetylase inhibitors
AU2006282896A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
US8759400B2 (en) * 2005-12-19 2014-06-24 Methylgene Inc. Histone deacetylase inhibitors for enhancing activity of antifungal agents
CA2641308A1 (en) 2006-02-06 2007-08-16 Lixte Biotechnology Holdings, Inc. Use of phosphatases to treat tumors overexpressing n-cor
US8598168B2 (en) * 2006-04-07 2013-12-03 Methylgene Inc. Inhibitors of histone deacetylase
US20090018142A9 (en) * 2006-05-02 2009-01-15 Zhengping Zhuang Use of phosphatases to treat tumors overexpressing N-CoR
CN103788108B (zh) 2007-02-06 2017-04-12 利克斯特生物技术公司 氧杂双环庚烷和氧杂双环庚烯，它们的制备及用途
WO2009020565A1 (en) * 2007-08-03 2009-02-12 Lixte Biotechnology, Inc. Use of phosphates to treat neuroblastomas and medullogastomas
CN101854804B (zh) 2007-10-01 2014-07-23 利克斯特生物技术公司 Hdac抑制剂
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
AU2009277086B2 (en) 2008-08-01 2015-12-10 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
WO2010014141A1 (en) 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
US20120135522A1 (en) 2009-06-18 2012-05-31 Kovach John S Methods of modulating cell regulation by inhibiting p53

Also Published As

Publication number Publication date
CA2700857A1 (en) 2009-04-09
CN101854804B (zh) 2014-07-23
US20090143445A1 (en) 2009-06-04
CA2700857C (en) 2016-08-02
EP2200439A4 (en) 2011-11-02
US20120178783A1 (en) 2012-07-12
US8143445B2 (en) 2012-03-27
AU2008307541B2 (en) 2015-02-12
AU2008307541A1 (en) 2009-04-09
EA018618B1 (ru) 2013-09-30
JP5730575B2 (ja) 2015-06-10
EA201070428A1 (ru) 2010-10-29
EP2200439A1 (en) 2010-06-30
MX2010003417A (es) 2010-09-10
US8455688B2 (en) 2013-06-04
JP2010540633A (ja) 2010-12-24
WO2009045440A1 (en) 2009-04-09
ES2628748T3 (es) 2017-08-03
CN101854804A (zh) 2010-10-06
EP2200439B1 (en) 2017-03-22

Similar Documents

Publication Publication Date Title
BRPI0816553A2 (pt) "composto, composição farmcêutica, uso de uma composição, uso de um composto, e, processo para a preparação de um composto"
BRPI0818533A2 (pt) composto, composição farmacêutica, e, processo para a preparação de um composto
BRPI0717695A2 (pt) "composição, uso de uma compsição e processo de preparação de uma composição"
BRPI0815405A2 (pt) Compostos derivados de purina, processo para a preparação de uma composição farmacêutica e uso dos mesmos
BRPI1006162A2 (pt) "composto,processo para preparar um composto,formulação farmacêutica,e uso de um composto".
BRPI0810696A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0611956A2 (pt) composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto
BRPI0810161A2 (pt) Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto
BRPI0906064A2 (pt) "peptídeo, processo para obtenção de um peptídeo de fórmula geral (i), composição cosmética ou farmacêutica e uso de um peptídeo de fórmula geral (i)"
BRPI0816331A2 (pt) Composto, uso de um composto, composição farmacêutica, e, processo para preparar um composto.
BRPI0915084A2 (pt) composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, métodos para a profilaxia ou tratamento de um estado de doença ou uma condição e de câncer
BRPI0717699A2 (pt) "composição e seus processos de preparação, uso de uma composição e uso coméstico de uma composição!
BRPI0719497A2 (pt) "composição, processo de preparação de uma composição, usos de uma composição e uso coméstico de uma composição"
BRPI0607423A2 (pt) forma microcristalina de um composto, processo para a preparação da mesma, uso de uma forma microcristalina, composição farmacêutica e processo para a preparação da mesma, e, produto
BRPI0819799A2 (pt) Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença
BRPI0609802A2 (pt) composto, composição farmacêutica e uso de um composto
BRPI0918487A2 (pt) processo para a preparação de uma composição de copolímero, composição, e, uso de uma composição de copolímero
BRPI0719488A2 (pt) "composição, processo de preparação da composição, uso de uma composição e uso cosmético de uma composição"
BRPI0815079A2 (pt) Composto dericado de 1,2-diamido-etileno, composição farmacêutica que contém e uso desse composto
BRPI0914371A2 (pt) "composto, composição farmacêutica, uso de um composto, método para tratar um indivíduo, e produto de combinação"
BR112012016201A2 (pt) ''composto, processo para a preparação de um composto, composição farmacêutica e uso de um composto''
BRPI0810019A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0812942A2 (pt) Composto, composição farmacêutica e uso de um composto
BR112012004173A2 (pt) "composto, composição, método para preparar uma composição, e, uso de um composto"
BRPI0716698A2 (pt) Composto, composição farmacêutica e uso de um composto

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2598 DE 20-10-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.